FibroGen Company Profile (NASDAQ:FGEN)

About FibroGen (NASDAQ:FGEN)

FibroGen logoFibroGen, Inc. is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FGEN
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.46204 billion
  • Outstanding Shares: 69,944,000
Average Prices:
  • 50 Day Moving Avg: $32.24
  • 200 Day Moving Avg: $27.21
  • 52 Week Range: $15.60 - $35.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -30.60
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $178.19 million
  • Price / Sales: 13.93
  • Book Value: $2.04 per share
  • Price / Book: 17.40
  • EBIDTA: ($52,180,000.00)
  • Net Margins: -37.60%
  • Return on Equity: -36.41%
  • Return on Assets: -14.13%
  • Debt-to-Equity Ratio: 0.65%
  • Current Ratio: 4.27%
  • Quick Ratio: 4.27%
  • Average Volume: 460,752 shs.
  • Beta: 1.77
  • Short Ratio: 4.76
Frequently Asked Questions for FibroGen (NASDAQ:FGEN)

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen, Inc (NASDAQ:FGEN) released its earnings results on Tuesday, May, 9th. The company reported ($0.52) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.63) by $0.11. The business had revenue of $26.89 million for the quarter, compared to the consensus estimate of $26.02 million. FibroGen had a negative return on equity of 36.41% and a negative net margin of 37.60%. View FibroGen's Earnings History.

Where is FibroGen's stock going? Where will FibroGen's stock price be in 2017?

8 brokers have issued 12-month price objectives for FibroGen's stock. Their forecasts range from $31.00 to $52.00. On average, they anticipate FibroGen's share price to reach $42.67 in the next year. View Analyst Ratings for FibroGen.

Who are some of FibroGen's key competitors?

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:

  • Thomas B. Neff, Chairman of the Board, Chief Executive Officer, Founder
  • Pat Cotroneo, Chief Financial Officer, Vice President - Finance
  • Frank H. Valone M.D., Senior Fellow, Clinical Development
  • K. Peony Yu M.D., Chief Medical Officer
  • Jeffrey L. Edwards, Independent Director
  • Jeffrey William Henderson, Independent Director
  • Thomas F. Kearns Jr., Independent Director
  • Kalevi Kurkijarvi Ph.D., Independent Director
  • Rory B. Riggs, Independent Director

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who owns FibroGen stock?

FibroGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include ECOR1 CAPITAL, LLC Total Shares: 1,322,991 (1.90%), Omega Fund Management LLC (0.90%), Handelsbanken Fonder AB (0.34%), Boston Advisors LLC (0.25%), Strs Ohio (0.20%) and Acadian Asset Management LLC (0.11%). Company insiders that own FibroGen stock include Frank H Md Valone, K Peony Yu, Kalevi Kurkijarvi, Miguel Madero, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr, Thomas F Kearns, Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Who sold FibroGen stock? Who is selling FibroGen stock?

FibroGen's stock was sold by a variety of institutional investors in the last quarter, including Omega Fund Management LLC, Acadian Asset Management LLC and Capital Impact Advisors LLC. Company insiders that have sold FibroGen stock in the last year include K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Insider Buying and Selling for FibroGen.

Who bought FibroGen stock? Who is buying FibroGen stock?

FibroGen's stock was purchased by a variety of institutional investors in the last quarter, including Boston Advisors LLC, Handelsinvest Investeringsforvaltning, Russell Investments Group Ltd. and Strs Ohio. View Insider Buying and Selling for FibroGen.

How do I buy FibroGen stock?

Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FibroGen stock can currently be purchased for approximately $35.50.

MarketBeat Community Rating for FibroGen (NASDAQ FGEN)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  140
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for FibroGen (NASDAQ:FGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $42.67 (20.19% upside)

Analysts' Ratings History for FibroGen (NASDAQ:FGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$31.00MediumView Rating Details
7/10/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$50.00HighView Rating Details
6/26/2017Citigroup Inc.Reiterated RatingBuy$48.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
6/22/2017Stifel NicolausReiterated RatingBuy$32.00 -> $38.00LowView Rating Details
1/18/2017Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
11/9/2016Leerink SwannReiterated RatingBuy$52.00N/AView Rating Details
8/9/2016Credit Suisse GroupReiterated RatingBuy$37.00N/AView Rating Details
9/23/2015Lake Street CapitalInitiated CoverageHold$25.00N/AView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for FibroGen (NASDAQ:FGEN)
Earnings by Quarter for FibroGen (NASDAQ:FGEN)
Earnings History by Quarter for FibroGen (NASDAQ FGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.63)($0.52)$26.02 million$26.89 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.53)($0.54)$19.29 million$31.91 millionViewListenView Earnings Details
11/8/2016Q3($0.63)($0.38)$24.30 million$30.10 millionViewListenView Earnings Details
8/8/2016Q2$0.36$0.35$80.58 million$89.28 millionViewListenView Earnings Details
5/9/2016Q116($0.56)($0.45)$16.89 million$28.28 millionViewListenView Earnings Details
2/29/2016Q4($0.54)($0.85)$40.44 million$24.44 millionViewListenView Earnings Details
11/12/2015Q3($0.61)($0.74)$28.74 million$19.54 millionViewListenView Earnings Details
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details
5/12/2015Q115($0.53)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details
3/26/2015Q414($0.90)($0.82)$16.49 million$16.11 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for FibroGen (NASDAQ:FGEN)
2017 EPS Consensus Estimate: ($1.96)
2018 EPS Consensus Estimate: ($1.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.77)($0.48)($0.63)
Q2 20173($0.47)($0.43)($0.45)
Q3 20173($0.46)($0.22)($0.37)
Q4 20173($0.58)($0.45)($0.52)
Q1 20181($0.87)($0.87)($0.87)
Q2 20181($0.84)($0.84)($0.84)
Q3 20181$0.77$0.77$0.77
Q4 20181($0.76)($0.76)($0.76)
(Data provided by Zacks Investment Research)


Dividend History for FibroGen (NASDAQ:FGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for FibroGen (NASDAQ:FGEN)
Insider Ownership Percentage: 14.90%
Institutional Ownership Percentage: 43.87%
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)
Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2017Thomas B NeffCEOSell38,636$35.09$1,355,737.24View SEC Filing  
7/24/2017Thomas B NeffCEOSell18,900$35.06$662,634.00View SEC Filing  
7/17/2017Kalevi KurkijarviDirectorSell2,000$33.45$66,900.00View SEC Filing  
7/10/2017K Peony YuInsiderSell5,000$32.98$164,900.00View SEC Filing  
7/7/2017Thomas B NeffCEOSell38,636$33.38$1,289,669.68View SEC Filing  
7/6/2017Pat CotroneoVPSell4,000$34.00$136,000.00View SEC Filing  
7/6/2017Thomas B NeffCEOSell18,900$33.53$633,717.00View SEC Filing  
6/22/2017Pat CotroneoVPSell3,000$32.00$96,000.00View SEC Filing  
6/22/2017Thomas B NeffCEOSell38,636$31.52$1,217,806.72View SEC Filing  
6/19/2017Pat CotroneoVPSell5,500$30.00$165,000.00View SEC Filing  
6/16/2017Thomas B NeffCEOSell38,636$29.40$1,135,898.40View SEC Filing  
6/15/2017Kalevi KurkijarviDirectorSell2,000$28.50$57,000.00View SEC Filing  
6/14/2017K Peony YuInsiderSell3,721$28.95$107,722.95View SEC Filing  
6/12/2017Pat CotroneoVPSell2,891$28.75$83,116.25View SEC Filing  
6/12/2017Toshinari TamuraDirectorSell30,000$28.89$866,700.00View SEC Filing  
6/6/2017Thomas F Kearns JrDirectorSell18,000$28.71$516,780.00View SEC Filing  
5/31/2017Thomas B NeffCEOSell38,636$26.21$1,012,649.56View SEC Filing  
5/16/2017Kalevi KurkijarviDirectorSell2,000$27.40$54,800.00View SEC Filing  
5/16/2017Thomas B NeffCEOSell38,636$27.70$1,070,217.20View SEC Filing  
5/15/2017Thomas B NeffCEOSell18,900$27.75$524,475.00View SEC Filing  
5/10/2017K Peony YuInsiderSell5,000$26.38$131,900.00View SEC Filing  
4/25/2017K Peony YuInsiderSell5,000$28.00$140,000.00View SEC Filing  
4/25/2017Pat CotroneoVPSell6,500$28.00$182,000.00View SEC Filing  
4/25/2017Thomas B NeffCEOSell38,636$26.92$1,040,081.12View SEC Filing  
4/24/2017Thomas B NeffCEOSell18,900$26.35$498,015.00View SEC Filing  
4/17/2017Kalevi KurkijarviDirectorSell2,000$25.25$50,500.00View SEC Filing  
4/13/2017Thomas B NeffCEOSell38,636$24.79$957,786.44View SEC Filing  
4/4/2017Thomas B NeffCEOSell38,636$23.92$924,173.12View SEC Filing  
3/21/2017Thomas B NeffCEOSell38,636$24.34$940,400.24View SEC Filing  
3/20/2017Thomas B NeffCEOSell18,900$24.88$470,232.00View SEC Filing  
3/15/2017Thomas B NeffCEOSell38,636$25.07$968,604.52View SEC Filing  
2/16/2017Kalevi KurkijarviDirectorSell2,000$24.45$48,900.00View SEC Filing  
2/14/2017Thomas B NeffCEOSell38,636$23.94$924,945.84View SEC Filing  
2/13/2017Thomas B NeffCEOSell18,900$23.97$453,033.00View SEC Filing  
2/9/2017Thomas B NeffCEOSell37,798$23.46$886,741.08View SEC Filing  
1/27/2017Thomas B NeffCEOSell37,798$23.29$880,315.42View SEC Filing  
1/19/2017Kalevi KurkijarviDirectorSell2,000$24.90$49,800.00View SEC Filing  
1/12/2017Thomas B NeffCEOSell37,798$23.85$901,482.30View SEC Filing  
1/11/2017Pat CotroneoVPSell6,500$24.00$156,000.00View SEC Filing  
1/10/2017K Peony YuInsiderSell5,000$23.56$117,800.00View SEC Filing  
12/28/2016Thomas B NeffCEOSell37,798$20.74$783,930.52View SEC Filing  
12/16/2016Rory B RiggsDirectorSell20,000$20.87$417,400.00View SEC Filing  
12/13/2016Thomas B NeffCEOSell37,798$21.24$802,829.52View SEC Filing  
12/12/2016Pat CotroneoVPSell2,344$22.05$51,685.20View SEC Filing  
12/12/2016Thomas B NeffCEOSell18,899$21.48$405,950.52View SEC Filing  
11/29/2016Thomas B NeffCEOSell37,798$22.80$861,794.40View SEC Filing  
11/28/2016Thomas B NeffCEOSell18,899$22.74$429,763.26View SEC Filing  
11/18/2016Thomas F Kearns JrDirectorSell18,000$22.40$403,200.00View SEC Filing  
11/17/2016Thomas B NeffCEOSell37,798$22.29$842,517.42View SEC Filing  
11/1/2016Thomas B NeffCEOSell37,798$16.76$633,494.48View SEC Filing  
10/19/2016Thomas B NeffCEOSell37,798$17.75$670,914.50View SEC Filing  
10/18/2016Thomas B NeffCEOSell18,899$17.94$339,048.06View SEC Filing  
10/4/2016Thomas B NeffCEOSell18,899$20.67$390,642.33View SEC Filing  
10/3/2016Thomas B NeffCEOSell18,899$20.55$388,374.45View SEC Filing  
9/21/2016Thomas B NeffCEOSell37,798$21.66$818,704.68View SEC Filing  
9/14/2016K Peony YuInsiderSell2,345$18.66$43,757.70View SEC Filing  
9/12/2016Pat CotroneoVPSell2,345$18.22$42,725.90View SEC Filing  
9/9/2016Thomas B NeffCEOSell37,798$18.99$717,784.02View SEC Filing  
8/26/2016Thomas B NeffCEOSell37,798$17.80$672,804.40View SEC Filing  
7/27/2016Thomas B NeffCEOSell37,798$18.38$694,727.24View SEC Filing  
7/13/2016Thomas B NeffCEOSell27,000$17.50$472,500.00View SEC Filing  
6/29/2016Thomas B NeffCEOSell27,000$16.02$432,540.00View SEC Filing  
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04View SEC Filing  
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.00View SEC Filing  
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24View SEC Filing  
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.00View SEC Filing  
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.00View SEC Filing  
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20View SEC Filing  
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.00View SEC Filing  
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.00View SEC Filing  
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.00View SEC Filing  
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.00View SEC Filing  
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50View SEC Filing  
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.00View SEC Filing  
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.00View SEC Filing  
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00View SEC Filing  
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.00View SEC Filing  
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.00View SEC Filing  
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.50View SEC Filing  
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.00View SEC Filing  
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.00View SEC Filing  
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76View SEC Filing  
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.00View SEC Filing  
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00View SEC Filing  
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.00View SEC Filing  
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.00View SEC Filing  
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28View SEC Filing  
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.14View SEC Filing  
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00View SEC Filing  
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00View SEC Filing  
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.00View SEC Filing  
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00View SEC Filing  
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.00View SEC Filing  
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00View SEC Filing  
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00View SEC Filing  
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00View SEC Filing  
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00View SEC Filing  
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.00View SEC Filing  
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.00View SEC Filing  
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00View SEC Filing  
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.00View SEC Filing  
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00View SEC Filing  
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00View SEC Filing  
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.00View SEC Filing  
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.00View SEC Filing  
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.00View SEC Filing  
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.00View SEC Filing  
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35View SEC Filing  
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00View SEC Filing  
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.00View SEC Filing  
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12View SEC Filing  
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00View SEC Filing  
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.00View SEC Filing  
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.00View SEC Filing  
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.00View SEC Filing  
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for FibroGen (NASDAQ:FGEN)
Latest Headlines for FibroGen (NASDAQ:FGEN)
DateHeadline logoFibroGen, Inc (NASDAQ:FGEN) CEO Sells $662,634.00 in Stock - July 26 at 7:58 PM logoThomas B. Neff Sells 38,636 Shares of FibroGen, Inc (NASDAQ:FGEN) Stock - July 26 at 7:17 PM logoGoldman Sachs Group, Inc. (The) Lowers FibroGen, Inc (NASDAQ:FGEN) to Neutral - July 22 at 7:34 PM logoCongress Could Have Major Impact on Biotech Companies - PR Newswire (press release) - July 21 at 10:03 PM logoTeligent Shares Rise on FDA Approval for Erythromycin Topical Gel ... - - July 21 at 10:03 PM logoFibroGen, Inc (NASDAQ:FGEN) Receives Consensus Rating of "Buy" from Analysts - July 21 at 11:43 AM logoBiotech Movers: Vertex Continues to Move on Data for CF Regimen - - July 20 at 4:17 PM logo$34.80 Million in Sales Expected for FibroGen, Inc (FGEN) This Quarter - July 19 at 4:54 PM logoContrasting Adamas Pharmaceuticals (ADMS) and FibroGen (NASDAQ:FGEN) - July 19 at 8:51 AM logoFibroGen, Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares - July 18 at 7:52 PM logoZacks: Brokerages Expect FibroGen, Inc (NASDAQ:FGEN) Will Post Earnings of -$0.47 Per Share - July 17 at 10:49 AM logoBrokers Issue Forecasts for FibroGen, Inc's Q2 2017 Earnings (NASDAQ:FGEN) - July 13 at 10:50 AM logoFibroGen, Inc (FGEN) Insider Sells $164,900.00 in Stock - July 11 at 10:52 PM logoFibroGen, Inc (FGEN) Coverage Initiated by Analysts at Jefferies Group LLC - July 10 at 5:26 PM logoFibroGen, Inc (FGEN) VP Sells $136,000.00 in Stock - July 7 at 8:41 PM logoFibroGen, Inc (FGEN) CEO Thomas B. Neff Sells 18,900 Shares - July 7 at 8:16 PM logoFibroGen, Inc (FGEN) to Post Q2 2017 Earnings of ($0.45) Per Share, William Blair Forecasts - June 28 at 7:32 AM logoFibroGen, Inc (FGEN) Given Buy Rating at Citigroup Inc. - June 26 at 5:50 PM logoFibroGen, Inc (FGEN) Receives Consensus Recommendation of "Buy" from Analysts - June 26 at 10:53 AM logoFibroGen, Inc (FGEN) Rating Reiterated by William Blair - June 26 at 8:16 AM logoFibroGen, Inc (FGEN) Rating Increased to Strong-Buy at BidaskClub - June 24 at 7:20 PM logoFibroGen, Inc (FGEN) VP Pat Cotroneo Sells 3,000 Shares - June 23 at 7:32 PM logoInsider Selling: FibroGen, Inc (FGEN) CEO Sells 38,636 Shares of Stock - June 23 at 7:15 PM logo Analysts Expect FibroGen, Inc (FGEN) Will Announce Quarterly Sales of $34.74 Million - June 23 at 6:58 PM logoStifel Nicolaus Reiterates Buy Rating for FibroGen, Inc (FGEN) - June 22 at 8:34 PM logoFibroGen's Pamrevlumab Gets Orphan Drug Designation To Treat Pancreatic Cancer - Nasdaq - June 22 at 9:46 AM logoFibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer - June 22 at 9:46 AM logoFibroGen, Inc (FGEN) VP Sells $165,000.00 in Stock - June 21 at 8:05 PM logo Analysts Expect FibroGen, Inc (FGEN) to Post -$0.48 Earnings Per Share - June 21 at 7:46 AM logoInsider Selling: FibroGen, Inc (FGEN) Director Sells 2,000 Shares of Stock - June 19 at 7:57 PM logoFibroGen, Inc (FGEN) Insider K Peony Yu Sells 3,721 Shares - June 16 at 7:58 PM logoPat Cotroneo Sells 2,891 Shares of FibroGen Inc (FGEN) Stock - June 14 at 8:19 PM logoToshinari Tamura Sells 30,000 Shares of FibroGen, Inc (FGEN) Stock - June 14 at 7:44 AM logoAbout FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference - June 13 at 7:23 AM logoInsider Selling: FibroGen Inc (FGEN) Director Sells 18,000 Shares of Stock - June 8 at 10:30 PM logoFibroGen (FGEN) Announces European Patent Office Decision to Maintain Patent Relating to Hypoxia-Inducible Factor ... - - June 5 at 11:15 AM logoEuropean Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology - June 5 at 11:14 AM logoFibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : June 2, 2017 - June 2 at 6:31 PM logoETFs with exposure to FibroGen, Inc. : June 2, 2017 - June 2 at 6:31 PM logoInsider Selling: FibroGen Inc (FGEN) CEO Sells 38,636 Shares of Stock - June 1 at 10:34 PM logo$34.74 Million in Sales Expected for FibroGen Inc (FGEN) This Quarter - May 27 at 7:33 AM logoZacks: Brokerages Anticipate FibroGen Inc (FGEN) Will Announce Earnings of -$0.48 Per Share - May 26 at 12:30 AM logoETFs with exposure to FibroGen, Inc. : May 22, 2017 - May 22 at 4:50 PM logoFibroGen, Inc. :FGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 - May 19 at 4:56 PM logoFibroGen Inc (FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares - May 17 at 11:15 PM logoInsider Selling: FibroGen Inc (FGEN) CEO Sells 18,900 Shares of Stock - May 17 at 10:51 PM logoFibroGen Inc (FGEN) CEO Thomas B. Neff Sells 38,636 Shares - May 17 at 10:28 PM logoAkebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact - May 15 at 4:50 PM logoInsider Selling: FibroGen Inc (FGEN) Insider Sells 5,000 Shares of Stock - May 12 at 8:01 PM logoEquities Analysts Offer Predictions for FibroGen Inc's FY2017 Earnings (FGEN) - May 12 at 12:54 PM



FibroGen (FGEN) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff